| Christopher C Duros, MD | |
|
8 Prospect St, Behavioral Health Unit, Nashua, NH 03060-3925 | |
| (603) 577-5720 | |
| (312) 276-8715 |
| Full Name | Christopher C Duros |
|---|---|
| Gender | Male |
| Speciality | Psychiatry & Neurology - Psychiatry |
| Location | 8 Prospect St, Nashua, New Hampshire |
| Accepts Medicare Assignments | Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1497849921 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 2084P0800X | Psychiatry & Neurology - Psychiatry | 35691 (Arizona) | Primary |
| Entity Name | Riverbend Community Mental Health, Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1942264940 PECOS PAC ID: 6103815584 Enrollment ID: O20040511000152 |
News Archive
Multiplexed genetic screening for epidermal growth factor receptor (EGFR) and anaplastic lymphoma kinase (ALK) gene rearrangements and subsequent biomarker-guided treatment is cost-effective compared with standard chemotherapy treatment without any molecular testing in the metastatic non-small cell lung cancer (NSCLC) setting in the United States.
Mylan Inc. today announced that its subsidiary Mylan Specialty L.P. has received final approval from the U.S. Food and Drug Administration for its Abbreviated New Drug Application for Levalbuterol Inhalation Solution USP, 0.31 mg/3 mL (0.0103%), 0.63 mg/3 mL (0.021%), and 1.25 mg/3 mL (0.042%), (Concentrate).
Scientists in the U.S. have found that a natural compound is just as effective as the widely used synthetic chemical repellent N,N-diethyl-3-methyl benzamide (DEET) against mosquitoes and ticks.
As its real costs become clearer, Obama's program is looking even more expensive for employers, seniors, and taxpayers (Rick Santorum, 6/16).
› Verified 1 days ago
| Entity Name | State Of New Hampshire |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1861491334 PECOS PAC ID: 3870530579 Enrollment ID: O20050414000166 |
News Archive
Multiplexed genetic screening for epidermal growth factor receptor (EGFR) and anaplastic lymphoma kinase (ALK) gene rearrangements and subsequent biomarker-guided treatment is cost-effective compared with standard chemotherapy treatment without any molecular testing in the metastatic non-small cell lung cancer (NSCLC) setting in the United States.
Mylan Inc. today announced that its subsidiary Mylan Specialty L.P. has received final approval from the U.S. Food and Drug Administration for its Abbreviated New Drug Application for Levalbuterol Inhalation Solution USP, 0.31 mg/3 mL (0.0103%), 0.63 mg/3 mL (0.021%), and 1.25 mg/3 mL (0.042%), (Concentrate).
Scientists in the U.S. have found that a natural compound is just as effective as the widely used synthetic chemical repellent N,N-diethyl-3-methyl benzamide (DEET) against mosquitoes and ticks.
As its real costs become clearer, Obama's program is looking even more expensive for employers, seniors, and taxpayers (Rick Santorum, 6/16).
› Verified 1 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Christopher C Duros, MD 8 Prospect St, Behavioral Health Unit, Nashua, NH 03060-3925 Ph: (603) 577-5720 | Christopher C Duros, MD 8 Prospect St, Behavioral Health Unit, Nashua, NH 03060-3925 Ph: (603) 577-5720 |
News Archive
Multiplexed genetic screening for epidermal growth factor receptor (EGFR) and anaplastic lymphoma kinase (ALK) gene rearrangements and subsequent biomarker-guided treatment is cost-effective compared with standard chemotherapy treatment without any molecular testing in the metastatic non-small cell lung cancer (NSCLC) setting in the United States.
Mylan Inc. today announced that its subsidiary Mylan Specialty L.P. has received final approval from the U.S. Food and Drug Administration for its Abbreviated New Drug Application for Levalbuterol Inhalation Solution USP, 0.31 mg/3 mL (0.0103%), 0.63 mg/3 mL (0.021%), and 1.25 mg/3 mL (0.042%), (Concentrate).
Scientists in the U.S. have found that a natural compound is just as effective as the widely used synthetic chemical repellent N,N-diethyl-3-methyl benzamide (DEET) against mosquitoes and ticks.
As its real costs become clearer, Obama's program is looking even more expensive for employers, seniors, and taxpayers (Rick Santorum, 6/16).
› Verified 1 days ago
Santharam Yadati, MD Psychiatry & Neurology Medicare: Accepting Medicare Assignments Practice Location: 436 Amherst St Ste 101, Nashua, NH 03063 Phone: 603-627-4764 Fax: 603-577-9595 | |
Pamela N Olsson, MD Psychiatry & Neurology Medicare: Medicare Enrolled Practice Location: 7 Prospect St., Nashua, NH 03060 Phone: 603-889-6147 Fax: 603-883-1568 | |
Dr. Kimberly K Whitesell, MD Psychiatry & Neurology Medicare: Not Enrolled in Medicare Practice Location: 7 Prospect St., Nashua, NH 03060 Phone: 603-889-6147 Fax: 603-883-1568 | |
Dr. Cynthia Brown Stevens, MD Psychiatry & Neurology Medicare: Not Enrolled in Medicare Practice Location: 7h Black Oak Dr, Nashua, NH 03062 Phone: 703-509-2753 | |
Bettina Peyton, M.D. Psychiatry & Neurology Medicare: Not Enrolled in Medicare Practice Location: 22 Prospect Street, Home Health & Hospice, Nashua, NH 03060 Phone: 603-882-2941 | |
Dr. Robert S Dealy, MD Psychiatry & Neurology Medicare: Not Enrolled in Medicare Practice Location: 7 Prospect St., Nashua, NH 03060 Phone: 603-889-6147 Fax: 603-883-1568 | |
Andreja Packard, MD PHD Psychiatry & Neurology Medicare: Accepting Medicare Assignments Practice Location: 17 Prospect St, Nashua, NH 03060 Phone: 603-577-5300 Fax: 603-577-5305 |